Aptinyx

United States
Clay, West Virginia, United States
(847)871-0377 ★

Company profile

Aptinyx company profile

Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. This mechanism has applicability across a number of CNS disorders. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need.

Business identity

Contact email
[email protected]
Phone number
(847)871-0377
Operating status
Active
Company type
For Profit
Employee range
00051-00100 employees
Revenue range
$0+
Founded
2015-01-01

Headquarters

Headquarters
Clay, West Virginia, United States
Postal code
60201
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Ipo
Funding rounds
6
Total equity funding
$183.3M
Last funding
Grant / $5.6M / 2022-11-03
Last equity funding
Post Ipo Equity / $48.3M
Investors
22
Lead investors
4
Founders
1
Articles
58
Exited on
2018-06-21

Founders and investors

Founders

Joseph Moskal

Lead investors

Bain Capital Life SciencesK2 HealthVenturesNational Institutes of HealthNew Leaf Venture Partners

Investors

Adage Capital ManagementAdams Street PartnersBain Capital Life SciencesLongitude CapitalOUP (Osage University Partners)

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.